Pharmexa and Bavarian Nordic initiate new NIH funded Phase I trial of HIV vaccines in combination
Marc Hertz, CEO of Pharmexa-Epimmune said: "This is an important milestone for Pharmexa as we continue our efforts to develop HIV vaccines in collaboration with the NIH. We are still searching for the best method to deliver epitopes in the HIV setting and this approach, DNA prime: MVA boost, is one of the most promising approaches in this field."
The study vaccines were developed by a Pharmexa-led consortium through a contract with NIAID, which to date has provided more than USD 10.0 million to develop a broad HIV vaccine for worldwide use with a population coverage across all ethnic and racial populations. Pharmexa and Bavarian Nordic share the marketing rights for both vaccines.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.